Press release content from Business Wire. The AP news staff was not involved in its creation.
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
April 12, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 12, 2021
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini’s Chief Medical Officer, effective immediately.
“We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. “As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus decades of clinical and development experience, as well
Paul Brassil of
Medfield has joined the company as senior vice president/chief information officer and will oversee PCU’s information technology and digital innovation efforts.
Brassil has more than 25 years of experience in the information technology leadership field with entities such as Commonwealth Medicine (a division of UMass Medical School), the Federal Reserve Bank of Boston, EMC Corp. and Siemens IT Solutions and Services Inc.
He holds an MS in computer information systems from Bentley University in
Waltham and a BA in Business Administration from Bridgewater State University.
Brassil s community involvement spans initiatives focused on workforce development and industry leadership serving as a member of the Tech Hire Advisory Group of Boston’s Private Industry Council (comprised of Boston CIOs developing summer intern programs for low/moderate income students in the Boston Public Schools); an adviser for Fintech Women (helping women in banking/finance/fintech a
The American Cancer Society and Pfizer Launch Community Grants Focused on Reducing Prostate Cancer Disparities Among Black Men
News provided by
Share this article
Share this article
ATLANTA, March 3, 2021 /PRNewswire/ The American Cancer Society and Pfizer Global Medical Grants are collaborating and have awarded a new competitive grant opportunity focused on addressing prostate cancer disparities impacting Black men.
The grants, funded by Pfizer Global Medical Grants and overseen by the American Cancer Society, are aimed at reducing gaps in care and barriers to treatment, and were awarded through a competitive selection process.
Cancer is a disease that affects everyone, but it doesn t affect everyone equally. Blacks experience more illness, worse outcomes, and premature death compared to whites in the United States. Further, Black people have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also have th
The American Cancer Society and Pfizer Launch Community Grants Focused on Reducing Prostate Cancer Disparities Among Black Men prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 08, 2021 07:30 ET | Source: Dyne Therapeutics, Inc. Dyne Therapeutics, Inc. Waltham, Massachusetts, UNITED STATES
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease
WALTHAM, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Ashish Dugar, Ph.D., MBA, as senior vice president, global head of medical affairs. Dr. Dugar brings over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation.